Cargando…
Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial
BACKGROUND: The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastol...
Autores principales: | Prochaska, Jürgen H., Jünger, Claus, Schulz, Andreas, Arnold, Natalie, Müller, Felix, Heidorn, Marc William, Baumkötter, Rieke, Zahn, Daniela, Koeck, Thomas, Tröbs, Sven-Oliver, Lackner, Karl J., Daiber, Andreas, Binder, Harald, Shah, Sanjiv J., Gori, Tommaso, Münzel, Thomas, Wild, Philipp S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293456/ https://www.ncbi.nlm.nih.gov/pubmed/36763159 http://dx.doi.org/10.1007/s00392-023-02164-w |
Ejemplares similares
-
Protective behavior and SARS-CoV-2 infection risk in the population – Results from the Gutenberg COVID-19 study
por: Baumkötter, Rieke, et al.
Publicado: (2022) -
Sex-Specific Relationship Between Parathyroid Hormone and Platelet Indices in Phenotypes of Heart Failure—Results From the MyoVasc Study
por: Dahlen, Bianca, et al.
Publicado: (2021) -
Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population
por: Schmitt, Volker H., et al.
Publicado: (2021) -
Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
por: Schmitt, Volker H., et al.
Publicado: (2021) -
Medical appointments and provision of medical care during the COVID-19 pandemic in Mainz, Germany
por: Schepers, Markus, et al.
Publicado: (2023)